AQP5 promotes epithelial-mesenchymal transition and tumor growth through activating the Wnt/β-catenin pathway in triple-negative breast cancer DOI

Zhengcai Zhu,

Tao Li,

Honggang Wang

и другие.

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, Год журнала: 2024, Номер 829, С. 111868 - 111868

Опубликована: Июнь 12, 2024

Язык: Английский

Modified EBP‐bFGF targeting endogenous renal extracellular matrix protects against renal ischemia‐reperfusion injury in rats DOI
Xiaoge Li, Chunying Shi,

Runxue Zhou

и другие.

Journal of Biomedical Materials Research Part A, Год журнала: 2024, Номер 112(10), С. 1827 - 1839

Опубликована: Май 3, 2024

Abstract Acute kidney injury (AKI) is a life‐threatening disease primarily caused by renal ischemia‐reperfusion (I/R) injury, which can result in failure. Currently, growth factor therapy considered promising and effective approach for AKI treatment. Basic fibroblast (bFGF), an angiogenic with potent activity, efficiently stimulates angiogenesis facilitates regeneration of tissue. However, the unrestricted diffusion bFGF restricts its clinical application Therefore, developing novel sustained released system could enhance potential treating AKI. In this study, we genetically engineered multifunctional recombinant protein fusing specific peptide (EBP). EBP‐bFGF effectively binds to extracellular matrix injured kidney, enabling slow release Furthermore, following orthotopic injection into I/R rats' ischemic kidneys, exhibited stable retention within Additionally, suppressed apoptosis cells, reduced fibrosis, facilitated recovery function. These findings suggest that delivery represents strategy

Язык: Английский

Процитировано

2
Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study DOI Creative Commons
Liping Tong,

Yuming Wan,

Xiaoxiao Shi

и другие.

Cancer Control, Год журнала: 2024, Номер 31

Опубликована: Янв. 1, 2024

Objective To evaluate the effectiveness of oral probiotic supplements in patients undergoing immune checkpoint inhibitors (ICIs) for treatment advanced lung cancer. Methods This prospective real-world study enrolled with cancer who were receiving ICIs as part their treatment. The divided into 2 groups: Group OPS received along ICIs, while C did not. primary endpoint was progression-free survival (PFS). secondary outcome measure objective response rate (ORR). Results A total 253 included study, 71 and 182 control group (Group C). No significant differences observed median PFS between groups all patients. However, small cell (SCLC) patients, significantly better compared to (11.1 months vs 7.0 months, P = .049). non-small (NSCLC) cohort groups, but a trend towards noticed (16.5 12.3 .56). ORR entire 58.0%. Conclusion Oral probiotics combination regimen may improve SCLC. above points should be proved by further study.

Язык: Английский

Процитировано

2
Epigenetic regulation of autophagy by non-coding RNAs and exosomal non-coding RNAs in colorectal cancer: A narrative review DOI
Minghua Liu, Hongfang Jiang, Mohammad Momeni

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 273, С. 132732 - 132732

Опубликована: Май 31, 2024

Язык: Английский

Процитировано

2
Circular RNAs in lung cancer: implications for preventing therapeutic resistance DOI Creative Commons
Wenjuan Liu, Yawen Sun, Yanfei Huo

и другие.

EBioMedicine, Год журнала: 2024, Номер 107, С. 105309 - 105309

Опубликована: Авг. 26, 2024

Язык: Английский

Процитировано

2
AQP5 promotes epithelial-mesenchymal transition and tumor growth through activating the Wnt/β-catenin pathway in triple-negative breast cancer DOI

Zhengcai Zhu,

Tao Li,

Honggang Wang

и другие.

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, Год журнала: 2024, Номер 829, С. 111868 - 111868

Опубликована: Июнь 12, 2024

Язык: Английский

Процитировано

2